Literature DB >> 21354058

Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content.

Coren A Milbury1, Clark C Chen, Harvey Mamon, Pingfang Liu, Sandro Santagata, G Mike Makrigiorgos.   

Abstract

Thorough screening of cancer-specific biomarkers, such as DNA mutations, can require large amounts of genomic material; however, the amount of genomic material obtained from some specimens (such as biopsies, fine-needle aspirations, circulating-DNA or tumor cells, and histological slides) may limit the analyses that can be performed. Furthermore, mutant alleles may be at low-abundance relative to wild-type DNA, reducing detection ability. We present a multiplex-PCR approach tailored to amplify targets of interest from small amounts of precious specimens, for extensive downstream detection of low-abundance alleles. Using 3 ng of DNA (1000 genome-equivalents), we amplified the 1 coding exons (2-11) of TP53 via multiplex-PCR. Following multiplex-PCR, we performed COLD-PCR (co-amplification of major and minor alleles at lower denaturation temperature) to enrich low-abundance variants and high resolution melting (HRM) to screen for aberrant melting profiles. Mutation-positive samples were sequenced. Evaluation of mutation-containing dilutions revealed improved sensitivities after COLD-PCR over conventional-PCR. COLD-PCR improved HRM sensitivity by approximately threefold to sixfold. Similarly, COLD-PCR improved mutation identification in sequence-chromatograms over conventional PCR. In clinical specimens, eight mutations were detected via conventional-PCR-HRM, whereas 12 were detected by COLD-PCR-HRM, yielding a 33% improvement in mutation detection. In summary, we demonstrate an efficient approach to increase screening capabilities from limited DNA material via multiplex-PCR and improve mutation detection sensitivity via COLD-PCR amplification.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354058      PMCID: PMC3128575          DOI: 10.1016/j.jmoldx.2010.10.008

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  61 in total

1.  Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis.

Authors:  Gudrun H Reed; Carl T Wittwer
Journal:  Clin Chem       Date:  2004-08-12       Impact factor: 8.327

2.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.

Authors:  Jin Li; Lilin Wang; Harvey Mamon; Matthew H Kulke; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nat Med       Date:  2008-04-13       Impact factor: 53.440

3.  Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms.

Authors:  Kim De Leeneer; Ilse Coene; Bruce Poppe; Anne De Paepe; Kathleen Claes
Journal:  Clin Chem       Date:  2008-04-10       Impact factor: 8.327

4.  Proliferation and turnover of glial cells in the forebrain of young adult mice as studied by repeated injections of 3 H-thymidine over a prolonged period of time.

Authors:  R Kraus-Ruppert; J Laissue; H Bürki; N Odartchenko
Journal:  J Comp Neurol       Date:  1973-03-15       Impact factor: 3.215

5.  High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.

Authors:  Roy Bastien; Tracey B Lewis; Jason E Hawkes; John F Quackenbush; Thomas C Robbins; Juan Palazzo; Charles M Perou; Philip S Bernard
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

6.  High-resolution melting analysis for detection of internal tandem duplications.

Authors:  Cecily P Vaughn; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

7.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

Review 8.  Cancers exhibit a mutator phenotype: clinical implications.

Authors:  Lawrence A Loeb; Jason H Bielas; Robert A Beckman
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

9.  Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.

Authors:  G D Smith; B E Chadwick; C Willmore-Payne; J S Bentz
Journal:  J Clin Pathol       Date:  2007-10-01       Impact factor: 3.411

10.  High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.

Authors:  Hongdo Do; Michael Krypuy; Paul L Mitchell; Stephen B Fox; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2008-05-21       Impact factor: 4.430

View more
  13 in total

Review 1.  COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications.

Authors:  Florence Mauger; Alexandre How-Kit; Jörg Tost
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

2.  COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing.

Authors:  Coren A Milbury; Mick Correll; John Quackenbush; Renee Rubio; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2011-12-21       Impact factor: 8.327

Review 3.  Integrating liquid biopsies into the management of cancer.

Authors:  Giulia Siravegna; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2017-03-02       Impact factor: 66.675

4.  COLD-PCR: improving the sensitivity of molecular diagnostics assays.

Authors:  Coren A Milbury; Jin Li; Pingfang Liu; G Mike Makrigiorgos
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

5.  Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay.

Authors:  Cristian Ruiz; Jianmin Huang; Sarah F Giardina; Philip B Feinberg; Aashiq H Mirza; Manny D Bacolod; Steven A Soper; Francis Barany
Journal:  Hum Mutat       Date:  2020-02-17       Impact factor: 4.878

6.  Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment.

Authors:  E Castellanos-Rizaldos; Pingfang Liu; Coren A Milbury; Minakshi Guha; Angela Brisci; Laura Cremonesi; Maurizio Ferrari; Harvey Mamon; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2012-05-15       Impact factor: 8.327

7.  Enrichment of mutations in multiple DNA sequences using COLD-PCR in emulsion.

Authors:  Elena Castellanos-Rizaldos; Coren Audrey Milbury; G Mike Makrigiorgos
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

8.  High-resolution melting (HRM) re-analysis of a polyposis patients cohort reveals previously undetected heterozygous and mosaic APC gene mutations.

Authors:  Astrid A Out; Ivonne J H M van Minderhout; Nienke van der Stoep; Lysette S R van Bommel; Irma Kluijt; Cora Aalfs; Marsha Voorendt; Rolf H A M Vossen; Maartje Nielsen; Hans F A Vasen; Hans Morreau; Peter Devilee; Carli M J Tops; Frederik J Hes
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

9.  Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.

Authors:  Minakshi Guha; Elena Castellanos-Rizaldos; Pingfang Liu; Harvey Mamon; G Mike Makrigiorgos
Journal:  Nucleic Acids Res       Date:  2012-12-20       Impact factor: 16.971

Review 10.  Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.

Authors:  Manuel Caitano Maia; Meghan Salgia; Sumanta K Pal
Journal:  Nat Rev Urol       Date:  2020-03-17       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.